Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
Open Access
- 19 June 2019
- Vol. 5 (2), e001013
- https://doi.org/10.1136/rmdopen-2019-001013
Abstract
Objectives To assess incidence rates (IRs) of VTE in patients with rheumatoid arthritis (RA) on different DMARDs and DMARD switchers. Methods Adults with RA on a DMARD between 2007 and 2017 were studied in a US claims database. Conventional synthetic DMARD (csDMARD) users, first biologic/targeted synthetic DMARD (b/tsDMARD) users and b/tsDMARD switchers (from a b/tsDMARD to another b/tsDMARD) were followed for inpatient VTE (pulmonary embolism (PE)/deep vein thrombosis (DVT)). Crude and adjusted IR and 95% CIs of VTE were estimated. HRs for VTE were estimated via Cox regression. VTE risk was also evaluated by number of switches between b/tsDMARDs and in patients without a VTE history. Results The age and sex standardised IR (95% CI) of VTE (per 100 person-years) was 0.86 (0.70 to 1.03), 0.60 (0.52 to 0.68) and 0.58 (0.51 to 0.65) for b/tsDMARD switchers, first b/tsDMARD users and csDMARD users, respectively. After adjustment, b/tsDMARD switchers had an increased risk of VTE, compared with csDMARD users, HRadj (95% CI) being 1.36 (1.16 to 1.58), 1.36 (1.13 to 1.63) and 1.47 (1.18 to 1.83) for VTE, DVT and PE, respectively. Compared with first b/tsDMARD users, the HRadj (95% CI) for VTE was 1.35 (1.15 to 1.60) for first b/tsDMARD switchers and 1.48 (1.19 to 1.85) for second b/tsDMARD switchers. Conclusions In RA, b/tsDMARD switchers have a higher VTE risk compared with csDMARD users and first b/tsDMARD users. Switching b/tsDMARDs may be a proxy for higher disease severity or poorly controlled RA and an important confounder to consider in obtaining unbiased estimates of VTE risk in observational RA safety studies.Keywords
This publication has 51 references indexed in Scilit:
- Risk of deep vein thrombosis and pulmonary embolism in asthmaEuropean Respiratory Journal, 2012
- Venous thromboembolism: Epidemiology and magnitude of the problemBest Practice & Research Clinical Haematology, 2012
- Noncardiac vascular disease in rheumatoid arthritis: Increase in venous thromboembolic events?Arthritis & Rheumatism, 2011
- Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysisBMJ, 2011
- Determining the test characteristics of claims-based diagnostic codes for the diagnosis of venous thromboembolism in a medical service claims databasePharmacoepidemiology and Drug Safety, 2010
- Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid ArthritisValue in Health, 2010
- Venous thrombosis in the elderly: incidence, risk factors and risk groupsJournal of Thrombosis and Haemostasis, 2010
- Chronic Kidney Disease Increases Risk for Venous ThromboembolismJournal of the American Society of Nephrology, 2008
- Discontinuation of Methotrexate Therapy in Older Patients with Newly Diagnosed Rheumatoid ArthritisDrugs & Aging, 2008
- Epidemiology and Risk Factors for Venous ThrombosisSeminars in Hematology, 2007